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Flox as adjuvant treatment after chemo-radiotherapy and surgery in rectal cancer
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Objetive. Preliminary toxicity analysis of chemotherapy FLOX schedule as adjuvant treatment in stage III of rectal cancer.
Methods. From August/06 to May/12, 13 consecutive patients (p) with pathological stage III rectal cancer were treated with FLOX
as adjuvant chemotherapy after pre-operative chemo-radiotherapy (5-Fluorouracil 2 cycles with pelvic radiotherapy 50.4Gy) and
radical surgery. FLOX schedule included: 5-ﬂuorouracil bolus 500mg/m2 with leucovorin 500mg/m2 days 1, 8, 15, 21, 29 and 36
and oxaliplatin 85 mg/m2 days 1, 15 and 29, every 8 weeks for a total 2 cycles. Haematological and clinical toxicity evaluation
every week was performed.
Results. Median age: 60 years (range 46–68). Male/female: 7/6. Histological Grades G1/G2/G3: 1/10/2. Pathological stage IIIA/IIIB/IIIC:
3/9/1. A total of 23 cycles were delivered over 26 planned. Main CTC toxicity for p was: Anaemia G 1+2 in 9, Neutropenia G 1+2
in 6 and G 3 in 5, Plaquetopenia G 1+2 in 5, Nausea and emesis G 1+2 in 4, Diarrhea G 1+2 in 3 and G 3+4 in 5, and Neurotoxicity
G1+2 in 7 p. No toxic deaths were observed. In relation to Neutropenia G 3 and Diarrhea G 3–4 two p were hospitalised. Only 3
p (23%) completed full treatment plan, 6 p (41%) required 80% dose reduction and/or a median of 2 week doses were cancelled,
3 p (23%) did not received the second cycle for toxicity in the ﬁrst and underwent Mayo clinic schedule, and 1 p progressed with
lung metastases during the second cycle.
Conclusions. Preliminary results suggest that FLOX chemotherapy schedule after chemo-radiotherapy and surgery in rectal
cancer have a moderate-severe toxicity proﬁle with 23% treatment interruption, 41% dose reduction and 15% hospitalization
for G 3–4 toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.200
Hemostatic radiotherapy for bleeding from an advanced gastric cancer
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Introduction. Gastric bleeding from the primary tumor frequently occurs in patients with unresectable gastric cancer, requiring
palliative treatment, including hemostatic radiotherapy (RT).
Objetive. To evaluate the effectiveness of RT with 30Gy in 10 fractions to control the bleeding from an advanced gastric cancer.
Methods. We reviewed the data from all gastric cancer patients who required blood transfusions due to gastric bleeding and were
treated with RT with hemostatic intention at Vall d’Hebron Hospital between April 2009 and October 2012. Overall 15 patients
were analyzed, with a median age of 74 years (58–85). All patients required blood transfusions previous to RT, with a median of
hemoglobin (Hb) preRT of 6.7 g/dL. Patients were treated in a lineal accelerator with a total dose of 30Gy in 10 fractions. Due to
rapid medical decline, 2 patients stopped treatment at 21 and 18Gy.
Results. The palliative effect of hemostatic RT was evaluated both in subjective and objective manner. Subjective symptomatic
relief (cessation of hematemesis and manes) was conﬁrmed through patient observation and objective response was determined
by the requirement of blood transfusions after RT, and also comparing hemoglobin levels both before and after RT. Twelve out of
15 patients (80%) responded subjectively to RT. In the ﬁrst 3 months after RT, 4 patients required blood transfusion, in 3 of those
cases these was due to hematological toxicity secondary to chemotherapy. The median of Hb before, 1 month after RT and 3
months after RT were: 6.7 g/dL (5.6–8.1), 9.7 g/dL (8.8–11.4) and 9.7 (7.6–11.4), respectively. Two patients presented bleeding again,
one case 1 month and the other one 14 months after RT.
Conclusions. Hemostatic RT is an adequate treatment of bleeding fromanadvanced gastric cancer, andRTwith 30Gy in 10 fractions
seems to be an effective schema, especially in patients with a poor prognosis.
http://dx.doi.org/10.1016/j.rpor.2013.03.201
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Introduction. Hypofractionated radiotherapy has been shown to be effective in tumor control. Short course irradiation may be a
valuable treatment option for patient convenience, cost reduction and in patients with a short life expectancy because of age or
comorbidities or patients who are unable to participate in a more prolonged course because of different problems.
Materials and method. Twenty-ﬁve patients diagnosed of rectal adenocarcinoma were treated at the Hospital de l’Esperanc¸a in
Barcelona. There were 14 patients with severe comorbidities who were unable to receive chemotherapy, 6 patients too old, who
were unable to come to our hospital 25 days because they live far from our hospital and 5 patients with a rectal tumour and
resectable liver metastases. All patients were treated with a 18 MV linear accelerator and the total dose administered was 25 Gy
in 5 fractions. Surgery was performed after 7–10 days after radiotherapy; only 5/25 patients received postoperative chemotherapy
before hepatic surgery.
S218 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S211–S226
Results. There were no acute toxicity. Late toxicity were as follows: 20/25 patients had mild enteritis and 16/25 patients mild
rectitis. Overall and speciﬁc survival at 5 y was 40.6% and 48.8%. Local disease free survival at 5 y was 58.2%.
Conclusion. Hypofractionated irradiation is well tolerated. Short course radiotherapy, is a valid treatment option for patients unﬁt
for radiochemotherapy and for elderly patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.202
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Objective. The aim of this retrospective study was to assess the outcomes of hypofractionated treatment in patients with rectal
referred to our department.
Patients and methods. Between January 2002 and June 2012, 356 consecutive patients with pathologically conﬁrmed rectal cancer
were treated with neoadjuvant treatment in our department. We analyzed 19 patients treated with hypofractionated scheme.
The treatment schedule consisted of 3D conformal external radiotherapy hypofractionated (total dose of 25Gy in daily fractions
of 5Gy, 5 days per week) and surgery in the week immediately following the completion of radiotherapy.
Results. Gender: male 57.9%, female 42.1%. Median age was 78 years (range 50–85 years). Staging of the cancer was as follows:
31.6% M1, 42.1% N+ and 26.3% T3–T4N0. All patients completed the RT treatment without interruption and undergoing surgery
a week (2 AAP, 10 RAB, 2 Hartman, 3 palliative colostomies). With a median of follow-up of 11 months (range 1–33), OS at 1 and
2 years was of 64% and 55% respectively.The DFS at 1 and 2 years was 57% and 49%. Treatment was well tolerated presenting no
acute or chronic toxicity G3.
Conclusions. The standard treatment for advanced rectal cancer in our department is preoperative chemoradiation. In elderly
patients with comorbilities or metastatic disease the hypofractionated treatment is a good option. New studies indicate that
similar results are obtained with both schemes, with more cost effective and should be gradually incorporated into our practice.
http://dx.doi.org/10.1016/j.rpor.2013.03.203
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Introduction. The percentage of local relapse after radical treatment in rectal neoplasias is around 25%. 15% die without distant
disease and median survival without treatment is around 8 months. AIMS Assessment of recurrence treated with surgery plus
IOERT in our institution, in terms of locorregional control and toxicity.
Materials and methods. Retrospective study from March 2008 to January 2013 sixteen patients with rectal recurrence. They have
received IOERT as part of the rescue treatment. 37.5% are women and 62.5% men.The median age is 67 years (range 45–82 years).
The medium interval since the primary tumor is diagnosed to the recurrence is 20.71 months. 81.3% were asymptomatic to the
recurrence. Six of the sixteen patients examined received neoadjuvant radiotherapy (range 45–54Gy) and the other adjuvant
radiotherapy. The treatment volume was deﬁned by tumor size plus a margin that contains the area at risk; marked with surgical
clips for a correct display. The energy of electrons being used 9-15 MeV. The IOERT dose varies according to the surgical margin:
RO, R1, and R2 with 10, 12.5–15 and 17.5–20 respectively (90% isodose). Assessment of toxicity according to RTOG scale.
Results. With a follow-up of 58 months, the current overall survival of 68.8% is not statistically signiﬁcant (p=0.071) vs R0 vs
R2.The disease-free survival, distant and the local control is about 68.8%, 75% and 87.5%, respectively.The dominant pattern of
distant relapse: liver and lung. As for maximum acute toxicity was: grade II rectal 18.8%, moderate neuropathic pain 31.3% and
genitourinary in 18.8%. There were no late toxicity.
Conclusions. The use of IOERT in treatment of recurrent rectal can signiﬁcantly improve local control without increasing the
incidence and severity of toxicity. Individualized strategies and longer follow-up are needed.
http://dx.doi.org/10.1016/j.rpor.2013.03.204
